This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager NURSA Molecule Pages Link Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dai, Y. Articles by Faller, D. V. Search for Related Content PubMed PubMed Citation Articles by Dai, Y. Articles by Faller, D. V.

Sirtuin 1 Is Required for Antagonist-Induced Transcriptional Repression of Androgen-Responsive Genes by the Androgen Receptor

Cancer Research Center and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts 02118

Address all correspondence and requests for reprints to: Yan Dai or Douglas V. Faller, Cancer Research Center, Boston University School of Medicine, Boston, Massachusetts 02118. E-mail: yandai{at}bu.edu and dfaller{at}bu.edu.

Androgen antagonists or androgen deprivation is a primary therapeutic modality for the treatment of prostate cancer. Invariably, however, the disease becomes progressive and unresponsive to androgen ablation therapy (hormone refractory). The molecular mechanisms by which the androgen antagonists inhibit prostate cancer proliferation are not fully defined. In this report, we demonstrate that sirtuin 1 (SIRT1), a nicotinamide adenosine dinucleotide-dependent histone deacetylase (HDAC) linked to the regulation of longevity, is required for androgen antagonist-mediated transcriptional repression and growth suppression. Androgen antagonist-bound androgen receptor (AR) recruits SIRT1 and nuclear receptor corepressor to AR-responsive promoters and deacetylates histone H3 locally at the prostate-specific antigen promoter. Furthermore, SIRT1 down-regulation by small interfering RNA or by pharmacological means increased the sensitivity of androgen-responsive genes to androgen stimulation, enhanced the sensitivity of prostate cancer cell proliferative responses to androgens, and decreased the sensitivity of prostate cancer cells to androgen antagonists. In this study, we demonstrate the ligand-dependent recruitment of a class III HDAC into a corepressor transcriptional complex and a necessary functional role for a class III HDAC as a transcriptional corepressor in AR antagonist-induced transcriptional repression. Collectively, these findings identify SIRT1 as a corepressor of AR and elucidate a new molecular pathway relevant to prostate cancer growth and approaches to therapy.

NURSA Molecule Pages Link:

Nuclear Receptors:   AR

Coregulators:   Sirt1  |  NCOR

Ligands:   Dihydrotestosterone  |  Bicalutamide

This article has been cited by other articles:

				K. Wu, S. Katiyar, A. Witkiewicz, A. Li, P. McCue, L.-N. Song, L. Tian, M. Jin, and R. G. Pestell The Cell Fate Determination Factor Dachshund Inhibits Androgen Receptor Signaling and Prostate Cancer Cellular Growth Cancer Res., April 15, 2009; 69(8): 3347 - 3355. [Abstract] [Full Text] [PDF]

				Y. Zhao, K.-i. Takeyama, S. Sawatsubashi, S. Ito, E. Suzuki, K. Yamagata, M. Tanabe, S. Kimura, S. Fujiyama, T. Ueda, et al. Corepressive Action of CBP on Androgen Receptor Transactivation in Pericentric Heterochromatin in a Drosophila Experimental Model System Mol. Cell. Biol., February 15, 2009; 29(4): 1017 - 1034. [Abstract] [Full Text] [PDF]

				B. Jung-Hynes, M. Nihal, W. Zhong, and N. Ahmad Role of Sirtuin Histone Deacetylase SIRT1 in Prostate Cancer: A TARGET FOR PROSTATE CANCER MANAGEMENT VIA ITS INHIBITION? J. Biol. Chem., February 6, 2009; 284(6): 3823 - 3832. [Abstract] [Full Text] [PDF]